

A decorative horizontal bar with a blue segment on the left and a yellow segment on the right.

News Release

19 December 2018

SGX welcomes medical technology firm Biolidics Limited to Catalist

Singapore Exchange (SGX) today welcomed Biolidics Limited to its Catalist under the stock code "8YY".

Biolidics Limited is a Singapore-based medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for the treatment of cancer. These applications include cancer diagnosis, prognosis, treatment selection and treatment monitoring. Biolidics Limited is an associated company of Catalist-listed Clearbridge Health.

Mohamed Nasser Ismail, Head of Equity Capital Market (SME) and Head of Capital Market Development, SGX, said, "Singapore houses one of the region's biggest medical technology clusters and is at the forefront of many developments on the medical front. Biolidics joins the growing number of medtech companies looking to tap Asia's healthcare market and SGX looks forward to supporting the company as it further explores opportunities in diagnostics and other specialties."

Executive Director and CEO of Biolidics Limited, Mr. Ivan Lew, said, "With Biolidics' novel patented technology to separate and enrich cancer cells from blood, there is great potential for Biolidics' chances to grow and successfully exploit the opportunities in the cancer diagnostics industry. While Biolidics is entering a new phase with our listing on SGX, we will continue to use our collective passion and dedication to develop the Company and create value to our stakeholders."

With a market capitalisation of about S\$68 million, the listing of Biolidics Limited brings the total number of companies listed on [Catalist](#) to 214, with a combined market capitalisation of more than S\$10 billion. This listing will also strengthen SGX's healthcare cluster, which will now have 40 companies, with combined market capitalisation of more than S\$70 billion.

Biolidics Limited opened at S\$0.265 today.

-End-

About Biolidics Limited

Incorporated in 2009 and based in Singapore, Biolidics is a medical technology company focusing on the development of cell enrichment systems which, when combined with other analytical tests, have a wide range of applications for cancer diagnosis, prognosis, treatment selection and treatment monitoring.

Biolidics has developed the ClearCell® FX1 System, a fully automated IVD medical device which relies on a novel patented technology to separate and enrich cancer cells from blood.

Biolidics' ClearCell® FX1 System allows users of the system to perform liquid biopsies to test for the presence of cancer cells (specifically circulating tumour cells, or CTCs) in blood samples or perform further analysis on cancer cells.

Liquid biopsies (i.e. analysis of the circulating tumour cells in blood samples) have many applications throughout the various stages of a patient's cancer journey, from cancer screening and staging to personalised treatment, and post-cancer monitoring.

Biolidics' quality assurance capabilities have been recognised through its ISO 13485 certification, CE-IVD, US FDA Class I registration and CFDA Class I registration (for the MGI EasyCell System).

About Singapore Exchange

Singapore Exchange (SGX) is Asia's leading and trusted market infrastructure, operating equity, fixed income and derivatives markets to the highest regulatory standards. As Asia's most international, multi-asset exchange, SGX provides listing, trading, clearing, settlement, depository and data services, with about 40% of listed companies and over 80% of listed bonds originating outside of Singapore.

SGX is the world's most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN and offers commodities and currency derivatives products. Headquartered in AAA-rated Singapore, SGX is globally recognised for its risk management and clearing capabilities. For more information, please visit www.sgx.com.

Media Contact

Singh-Yeo Wan Xin
Marketing & Communications
+65 6713 6545
wanxin.singhyeo@sgx.com

Singapore Exchange Limited
Company Reg No. 199904940D

2 Shenton Way, #02-02 SGX Centre 1, Singapore 068804
main: +65 6236 8888 fax: +65 6535 6994
sgx.com